Clinical trial · Interventional
Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections
Effect of Dexmedetomidine on Postoperative Delirium in Patients Undergoing Brain Tumor Resections: a Randomized Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non cardiac surgery. Previous studies have reported that the total incidence of neurological pod ranged from 10% to 22%. Dexmedetomidine (DEX) is an a-2 adrenergic agonist for sedation. This kind of drug has little effect on respiratory function, is easy to wake up and has analgesic effect. It is a commonly used perioperative adjuvant drug. However, for neurosurgical patients with brain tumors, the role of DEX in POD is not clear. The purpose of this study was to investigate the effect of DEX on POD in neurosurgical brain tumor surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dexmedetomidine | — | UNRESOLVED | — |
| Postoperative Delirium | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 0.9% saline | Drug | — | UNRESOLVED |
| Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- DEX group
- description
- The DEX group will receives dexmedetomidine intraoperative.
- interventionNames
- Drug: Dexmedetomidine
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- description
- The placebo group will receives 0.9% saline intraoperative.
- interventionNames
- Drug: 0.9% saline
Primary outcomes (1)
- measure
- The incidence of postoperative delirium
- timeFrame
- postoperative 5 day
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing selective frontotemporal tumor resection. * Age ≥18 years. * Obtain written informed consent. Exclusion Criteria: * Refusal to provide written informed consent. * Preoperative severe cognitive impairment (mini-mental state examination, MMSE ≤ 20). * Allergic to the study drug. * History of psychotropic drugs within past 30 days. * Pregnant or lactating women. * History of traumatic brain injury or neurosurgery. * Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block. * Severe hepatic or renal dysfunction.
References
Publications (4)
- DERIVEDWu Y, Ren Y, Li S, Zeng M, Wang J, Li M, Peng Y. Association between intraoperative hypotension during brain tumor resection and postoperative delirium: A secondary analysis of a randomized controlled trial. PLoS One. 2025 Oct 29;20(10):e0334094. doi: 10.1371/journal.pone.0334094. eCollection 2025. PMID 41160633
- DERIVEDZeng M, Xu X, Li R, Zhang X, Ma T, Cui Q, Wang J, Li S, Peng Y. Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial. Anesth Analg. 2024 Apr 1;138(4):839-847. doi: 10.1213/ANE.0000000000006563. Epub 2023 Jun 12. PMID 37307232
- DERIVEDLi S, Li R, Li M, Cui Q, Zhang X, Ma T, Wang D, Zeng M, Li H, Bao Z, Peng Y, Sessler DI. Dexmedetomidine administration during brain tumour resection for prevention of postoperative delirium: a randomised trial. Br J Anaesth. 2023 Feb;130(2):e307-e316. doi: 10.1016/j.bja.2022.10.041. Epub 2022 Dec 13. PMID 36517290
- DERIVEDWang D, Li R, Li S, Wang J, Zeng M, Dong J, Liu X, Lin N, Peng Y. Effect of dexmedetomidine on postoperative delirium in patients undergoing brain tumour resections: study protocol of a randomised controlled trial. BMJ Open. 2021 Nov 10;11(11):e051584. doi: 10.1136/bmjopen-2021-051584. PMID 34758995